Anti-Infectives · LP-022
Nystatin Oral drops
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-022Anti-Infectives
- Generic identity
- NystatinOral drops
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-022
- Generic identity
- Nystatin
- Presentation
- Oral drops
- Catalogue strength
- 100,000 IU/mL
- Catalogue pack
- Bottle 30 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: nystatin.
- Dosage form recorded: oral drops.
- Catalogue concentration: 100,000 IU/mL.
- Catalogue pack: bottle 30 mL.
Layer 02 · Unresolved product-specific fields
- Exact potency/unit basis and whether “IU” is the controlled label expression for the intended product.
- Liquid vehicle, suspension/solution character, shaking requirement and calibrated dropper/oral syringe specification.
- Approved oral indication, age eligibility, administration/contact-time instructions and after-opening limits.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 100,000 IU/mL | Oral drops | — | Bottle 30 mL | Dropper calibration, liquid character and potency-unit expression require exact product evidence. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Nystatin is an antifungal medicine used in appropriate formulations for Candida and other susceptible yeast infections. An oral liquid acts in the mouth and gastrointestinal tract and should not be presented as treatment for an invasive bloodstream infection. The actual formulation and site of use matter. This educational profile does not establish approved Luang Pharma labeling, an exact excipient composition or suitability for a particular age group.
Clinical context and therapeutic role
Oral thrush requires distinction from other causes of a sore mouth or white patches. Predisposing factors such as dentures, recent antibiotics, inhaled corticosteroids or impaired immunity may need attention alongside antifungal therapy. Recurrent infection, difficulty swallowing or illness in a medically vulnerable patient warrants clinical assessment. The oral-drop description must be reconciled with the registered liquid formulation and its administration instructions before professional selection or patient counseling.
Selected safety context
Nausea, diarrhoea and local irritation may occur. Hypersensitivity is possible and requires assessment if rash or swelling develops. Difficulty breathing or rapidly progressing swelling is an emergency. A liquid intended for oral use should not be placed in the eyes or treated as a sterile ophthalmic preparation. Persistent symptoms, feeding difficulty or pain on swallowing need reassessment. Any sugar content, preservative or other excipient-related suitability must be checked from the actual label.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes oral drops, which must be reconciled with the exact registered liquid formulation and concentration. A drop count is not interchangeable with a measured volume unless the authorized device and instructions establish it. This route must be distinguished clearly from ophthalmic drops.
Use the supplied calibrated oral administration device as instructed and follow any mixing requirement in the leaflet. Avoid sharing or contaminating the applicator. Check the actual storage conditions and period after opening; neither is inferred from another manufacturer’s nystatin liquid.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification/formula with potency-unit basis.
Approved label/leaflet identifying oral presentation, measuring device and administration instructions.
Bottle/dropper/container-closure specification.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: NystatinArchived source classification: US National Library of Medicine medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-022.
Professional enquiries
Request product-specific evidence for LP-022.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.